Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
J.r. Bast RC, M. Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin, R.C. Knapp.
Reactivity of a monoclonal antibody with human ovarian carcinoma.
J Clin Invest, 68 (1981), pp. 1331-1337
[2.]
A. Jiménez Lacave, M. Allende Monclús.
Falsos negativos y positivos de los marcadores tumorales: sus limitaciones en la práctica clínica. Aplicaciones clínicas al CA-125.
Rev Clin Esp, 201 (2001), pp. 715-717
[3.]
J.r. Bast RC, T.L. Klug, E. St John, E. Jenison, J.M. Niloff, H. Lazarus, et al.
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
N Engl J Med, 309 (1983), pp. 883-887
[4.]
A. Sevine, C. Camci, H.M. Turk, S. Buyukberber.
How to interpret serum CA 125 levels in patients with serosal involvement?.
A clinical dilemma Oncology, 65 (2003), pp. 1-6
[5.]
C. Miralles, M. Orea, P. España, M. Provencio, A. Sánchez, B. Cantos, et al.
Cancer Antigen 125 associated with multiple benign and malignant pathologies.
Ann Surg Oncol, 10 (2003), pp. 150-154
[6.]
J.F. Bergmann, M. Beaugrand, H. Labadie, J.M. Bidart, C. Bohuon.
CA 125 (ovarian tumor-associated antigen) in ascitic liver diseases.
Clin Chim Acta, 155 (1986), pp. 163-165
[7.]
A. Ruibal, R. Siurana.
Evidence of a relationship between high serum CA 125 and liver failure pattern in cirrhotic patients without ascitis and jaundice.
Int J Biol Markers, 1 (1986), pp. 55-56
[8.]
E. Zuckerman, A. Lanir, E. Sabo, T. Rosenvald-Zuckerman, I. Matter, D. Yeshurun, et al.
Cancer Antigen 125: a sensitive marker of ascites in patients with liver cirrhosis.
Am J Gastroenterol, 94 (1999), pp. 1613-1617
[9.]
H. Devarbhavi, D. Kaese, A.W. Williams, J. Rakela, G.G. Klee, P.S. Kamath.
Cancer Antigen 125 in patients with chronic liver disease.
Mayo Clin Proc, 77 (2002), pp. 538-541
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
